Among the potential complications associated with the use of breast implants are the risks of periprosthetic infection and device extrusion. There is little published information about the effective management of these situations. Conservative recommendations include antibiotic therapy and removal of the implant until resolution of the infection or until the wound has healed. A retrospective review identified patients with periprosthetic infection or threatened or actual device exposure treated by the senior author. Twenty-four patients encompassing 26 affected prostheses were available for review and were classified into seven groups based on initial presentation as follows: group 1, mild infection (n ϭ 8); group 2, severe infection (n ϭ 4); group 3, threatened exposure without infection (n ϭ 3); group 4, threatened exposure with mild infection (n ϭ 3); group 5, threatened exposure with severe infection (n ϭ 1); group 6, actual exposure without clinical infection (n ϭ 5); and group 7, actual exposure with infection (n ϭ 2). To salvage the prosthesis in these patients, various treatment strategies were utilized. All patients with a suspected infection or device exposure were started immediately on appropriate antibiotic therapy (oral antibiotics for mild infections and parenteral antibiotics for severe infections). Salvage methods included one or more of the following: antibiotic therapy, débridement, curettage, pulse lavage, capsulectomy, device exchange, primary closure, and/or flap coverage. Twenty (76.9 percent) of 26 threatened implants with infection or threatened or actual prosthesis exposure were salvaged after aggressive intervention. The presence of severe infection adversely affected the salvage rate in this series. A statistically significant difference exists among those patients without infection or with mild infection only (groups 1, 3, 4, and 6); successful salvage was achieved in 18 (94.7 percent) of 19 patients, whereas only two of seven of those implants with severe infection (groups 2, 5, and 7) were salvaged (p ϭ 0.0017). Ten (90.9 percent) of 11 devices with threatened or actual exposure, not complicated by severe infection (groups 3, 4, and 6), were salvaged. Several treatment strategies were developed for periprosthetic infection and for threatened or actual implant exposure. Patients with infection were placed on oral or intravenous antibiotics; those who responded completely required no further treatment. For persistent mild infection or threatened or actual exposure, operative intervention was required, including some or all of the following steps: implant removal, pocket curettage, partial or total capsulectomy, débridement, site change, placement of a new implant, and/or flap coverage; the menu of options varied with the precise circumstances. No immediate salvage was attempted in five cases, due to either severe infection, nonresponding infection with gross purulence, marginal tissues, or lack of options for healthy tissue coverage. Based on the authors' experience, salvage attempts for periprosthetic infection and prosthesis exposure may be successful, except in cases of overwhelming infection or deficient soft-tissue coverage. Although an attempt at implant salvage may be offered to a patient, device removal and delayed reinsertion will always remain a more conservative and predictable option. (Plast. Reconstr. Surg. 113: 1634 Surg. 113: , 2004 .)
The use of breast implants for cosmetic and reconstructive procedures is increasingly common today. Approximately 219,000 augmentation mammaplasties and 82,000 breast reconstructions were performed in the year 2001 alone. 1 Common complications associated with the use of breast implants include capsular contracture, device failure, and implant malposition. Less frequent but more serious are the risks of infection and device extrusion.
Although virtually all studies 2-21 report a low incidence of infection or breast implant exposure, there is little published information on the management of these two complications. Early recommendations for these problems included antibiotic treatment alone and/or device removal with delayed replacement of the device. 17 Courtiss et al. 7 reported that 45 per-cent of patients with a periprosthetic infection characterized by drainage, erythema, swelling, and/or pain may be treated successfully with antibiotics, passive wound drainage, and healing by secondary intention. In their series, 68 percent of the salvaged implants developed symptomatic capsular contracture.
To provide further understanding of the management of these situations, the authors reviewed their experience with threatened prosthetic breast devices.
PATIENTS AND METHODS
A retrospective review of patients with prosthetic breast devices between 1990 and 2002 was conducted. Patients with infection or threatened/actual device exposure were identified. Demographic, treatment, and outcome data were collected and analyzed.
Patients presenting with clinical evidence of infection were classified as having either mild or severe infection. A mild infection was defined as warmth, swelling, or cellulitis without drainage that was responsive to initial antibiotic therapy. A severe infection was defined when one or more of the following were present: persistent, substantial swelling despite antibiotic therapy, purulent drainage with or without cellulitis, aggressive or atypical organisms on culture (e.g., Pseudomonas, mycobacteria, or Gram-negative rods), or serious signs and symptoms of systemic infection (e.g., hypotension or high fever).
Patients were classified into seven groups according to initial presentation (Table I) as follows: group 1-mild infection (n ϭ 8), minimal, localized erythema at the surgical site or in the skin overlying the implant; group 2-severe infection (n ϭ 4), significant generalized erythema, purulent drainage, and/or systemic signs of infection; group 3, threatened implant exposure without infection (n ϭ 3); group 4, threatened implant exposure with mild infection (n ϭ 3); group 5, threatened devices with concurrent severe infection (n ϭ 1); group 6, actual implant exposure with no or mild signs of infection (n ϭ 5); group 7, actual device exposure with significant or severe infection (n ϭ 2).
For purposes of this study, "implant salvage" was defined as continued presence of a prosthetic device after surgical intervention. Rather than actual retention of the original device, the goal was to maintain the results of the original procedure. If the device was exposed or periprosthetic infection was present, a new device was inserted at the time of the surgical intervention. To achieve successful, primary implant salvage, various modalities were utilized, depending on the findings (Table I) . Modalities included systemic antibiotic therapy, wound edge débridement, curettage, pulse lavage, capsulectomy, device position change (i.e., subglandular to subpectoral), device exchange, primary closure, and/or flap coverage. The outcome of each patient group was tabulated.
CASE REPORTS

Case 1: Group 2, Severe Infection
An 18-year-old patient underwent left augmentation mammaplasty and right mastopexy for congenital breast asymmetry ( Fig. 1) . Unbeknownst to the surgeon, the patient began postoperative acupuncture therapy to the augmented breast for pain control. On postoperative day 9, the patient developed erythema, clear fluid drainage, and slight dehiscence of the left periareolar incision. Over the next 4 months, the infection waxed and waned and was determined to involve the periprosthetic space. Antibiotic therapy was initiated to treat intermittent episodes of breast swelling and erythema and her indolent infection became quiescent. Six months after the original presentation, the patient underwent left capsulectomy and pulse lavage of the implant site. The surgical instruments were changed, the operative field re-prepared, and drapes, gloves, and gowns were changed. A new implant was inserted in the same, partially subpectoral site. Although intraoperative cultures were negative, antibiotic therapy continued for 3 weeks postoperatively. At 6 months, the patient was symptom-free without signs of infection or capsular contracture and achieved a satisfactory result.
Case 2: Group 3, Threatened Exposure without Infection
A 53-year-old patient underwent bilateral prophylactic mastectomies using Wise pattern incisions and immediate tissue expander placement in a partially submuscular space. During the week after surgery, bilateral partial flap loss was noted at the "T" junction of both breasts in an area without underlying muscle coverage (Fig. 2) . Although no obvious infection was noted, the patient was started on antibiotic therapy. On postoperative day 8, the patient underwent bilateral flap revision. After débridement of all compromised FIG. 1. Preoperative (left) and postoperative (right) photographs of a patient who underwent left breast augmentation for a congenital deformity. She was classified as group 2, as she developed a periprosthetic infection treated with a prolonged course of antibiotics, capsulectomy, and implant exchange. tissue, the devices were covered with clean, healthy, and viable soft tissue. Sufficient skin flaps remained to allow for simple closure of the wounds. The patient healed uneventfully and her expanders were exchanged to permanent implants 5 months later. She went on to heal with a satisfactory result, without capsular contracture.
Case 3: Group 4, Threatened Exposure with Mild Infection
A 55-year-old patient underwent bilateral subcutaneous mastectomies and immediate expander reconstruction (Fig.  3) . In the immediate postoperative period, bilateral necrosis of the inferior portion of the breast skin flaps associated with mild erythema was noted. The patient was started on oral antibiotic therapy. Two weeks after the mastectomies, the patient underwent a bilateral transverse rectus abdominis musculocutaneous (TRAM) flap salvage procedure to replace the breast skin loss. The expanders were left in place and were exchanged to permanent implants 4 months later. The patient achieved a satisfactory result without further infection or capsular contracture.
Case 4: Group 6, Actual Implant Exposure without Clinical Infection
A 36-year-old with a history of previous subglandular augmentation mammaplasty underwent three subsequent operations to correct capsular contracture and implant malposition. Ultimately, the patient was referred to the senior author when a 2-cm region of areola overlying the implant broke down and the implant became exposed (Fig. 4) . The patient desired an attempt at implant salvage; therefore, device removal, capsulectomy, and pulse lavage of the implant pocket were performed. A subpectoral pocket was created and a new device was inserted. The patient healed uneventfully through her 2-year follow-up.
RESULTS
Forty implants in 38 patients that were treated for infection, threatened device exposure, or actual device exposure were identified. Fourteen were excluded because of unavailable or incomplete records. Twenty-four patients' charts encompassing 26 affected pros- theses were available for review (Table II) . Two patients had bilateral implant salvage. Five (19.2 percent) of 26 devices were utilized for breast augmentation, whereas 21 (80.8 percent) of 26 devices were used for breast reconstruction. Nine (42.9 percent) of the 21 threatened reconstruction devices were in patients who received prior radiation therapy.
The eight patients who presented with minor or localized infection without exposure (group 1) were treated solely with oral or intravenous antibiotic therapy. All of these patients were successfully treated and retained their implants for an overall success rate of 100 percent.
In the four patients who had isolated severe infection without exposure (group 2), two augmentation patients were offered implant salvage that was ultimately successful. One patient's implant was salvaged with intravenous antibiotics, capsulectomy, device exchange, and site change. The other implant was salvaged by antibiotic therapy, capsulectomy, and device exchange, but without site change. As a result of overwhelming infection, two breast reconstruction patients were not offered an attempt at salvage and their implants were removed. The salvage rate among all patients with severe infection was only 50 percent.
Among the two breast reconstruction patients who presented with three threatened implant exposures without evidence of infection (group 3), one patient had bilateral threatened exposures in which the local soft tissues were adequate to allow for a successful local revision. In the other patient, a threatened device with inadequate local soft tissue was successfully salvaged with a latissimus dorsi flap. The overall salvage rate for threatened devices without infection was 100 percent. In the case of the three patients who presented with threatened exposure and minor infection (group 4), each patient was successfully treated with antibiotic therapy, capsulectomy, device exchange, and immediate distant flap coverage. One latissimus dorsi and one bilateral TRAM flap were utilized for implant salvage. The overall success rate was 100 percent.
The one patient who presented with threatened implant exposure and severe infection (group 5) had undergone prior two-stage expander/implant reconstruction and subsequent radiation therapy. To supplement the soft-tissue envelope, a TRAM flap was performed. There was partial flap loss and overwhelming infection with the obvious threat of implant exposure. This was treated by explantation without a salvage attempt. The overall salvage was 0 percent.
Among the five patients who presented with actual implant exposure without clinical evidence of active infection (group 6), two of the five had undergone breast augmentation. One of these was treated with capsulectomy, implant site change, and primary closure. Another was treated by implant pocket irrigation and simple wound closure. Of the three reconstruction patients, two reconstruction implants were successfully salvaged. One was treated with local skin flap revision and primary closure, and another with capsulotomy, irrigation, and primary closure. Primary closure was attempted in a third reconstruction patient, but this failed. The implant was subsequently removed and delayed reconstruction was performed. Overall, successful implant salvage was 80 percent in the setting of exposure without infection.
For the two patients (group 7) who experienced prosthesis exposure with severe infection, the implant was removed without an attempt at salvage. One patient sought delayed reconstruction, and a second was lost to followup. Thus, the success rate for implant salvage for exposure with severe infection was zero percent.
Of the 26 implants with infection or exposure, immediate salvage with either the original device or a new device was achieved in 20 cases (76.9 percent). In five of six failures, no significant effort had been made to save the implant given the overwhelming nature of the infection. Augmentation patients' devices were salvaged in five of five cases. In the setting of breast reconstruction, threatened devices were salvaged in 15 of 21 cases (71.4 percent).
Ultimately, only two of the six failures underwent delayed reconstruction, both with twostage expander/implant reconstruction. Among the 15 successful salvage attempts, subsequent revision surgery was required in four (26.7 percent). Three salvaged implants, all for breast reconstruction, subsequently required capsulectomy to treat capsular contracture, and one required a latissimus dorsi flap to augment the soft-tissue envelope.
Overall success rates were as follows: salvage of mild infections (group 1) was eight of eight, threatened exposure (group 3) was three of three, threatened exposure with mild infection (group 4) was three of three, and actual exposure (group 6) was four of five. Hence, overall success rate in the setting of mild or no infection was 18 of 19 (94.7 percent), whereas salvage in the severely infected groups (groups 2, 5, and 7) was two of seven. This difference was significant (p ϭ 0.0017) by two-sided Fisher's exact test. Both successes in the severely infected groups were in augmentation patients.
DISCUSSION
The senior author's interest in this subject originated with his 1998 publication 18 describing 171 expander and implant breast reconstructions. In that study, two expanders (1.2 percent) were prematurely removed because of infection. Disa et al. 8 subsequently reported a 1.4 percent premature removal rate resulting from infection, exposure, or skin necrosis. Others note that the rate of periprosthetic infection during augmentation mammaplasty ranges from 1.7 percent to 2.5 percent. 6 In the past, teaching held that infection in the setting of a breast prosthesis required implant removal and delayed reinsertion. 17 During the past 20 years, there has been a growing awareness that a periprosthetic infection or exposure does not necessarily condemn an implant to removal. 7, 19 Courtiss et al. 7 reported that in the setting of periprosthetic infection, successful implant salvage was achieved in 13 of 29 implants by passive wound drainage and antibiotic therapy. Courtiss et al. 7 subsequently recommended that active intervention is necessary to save implants with periprosthetic infection 13 and that capsulotomy and dissection should be performed to avoid skin tension during treatment of threatened implant exposure. 15 Others have discussed salvage as an op-tion, although some authors suggest that the management of such situations is a clinical judgment with few additional established guidelines. 2 In a rodent model, Marsh et al. 13 studied the effect of timing on implant reinsertion in the face of infection. They found that in the presence of infection, device removal, pocket irrigation, and immediate reaugmentation with a new device resulted in a 100 percent rate of reinfection and dehiscence. A reinsertion delay of two or more hours reduced the failure rate to 8.6 percent. Concomitant antibiotic therapy did not affect the outcome. In that study, the authors did not perform a capsulectomy, which arguably should be performed as part of an adequate wound débridement. There was also question as to the applicability of this model to humans. 13 There has been no further consensus as to the application of these findings to humans, and no subsequent recommendations have been published for delayed implant reinsertion based on these findings.
The literature contains several reports describing atypical infection and device exposure management on a case-by-case basis.
2,9,10 Recommendations include device removal and capsulectomy only, 12 removal of the implant with retention of capsule, 9 explantation with delayed reinsertion, 10,11 implant retention with local pocket irrigation catheters, 19 -21 local revision with implant retention or immediate reaugmentation, 11 local muscle flaps, 15 and fascia lata grafts. 15 Admittedly, there has been, and continues to be, an evolution in the authors' treatment strategies for the clinical scenarios reported in this series. Because of the small number of patients in this study and the lack of a control group, the authors' treatment strategies do not benefit from statistical significance. The authors also recognize that their experience in managing these patients does not rise to the level of a definitive treatment algorithm. Although this study lacked an ideal amount of scientific rigor, the authors felt it important to share strategies for the successful management of these patients without sacrifice of their surgical results (Figs. 5 and 6) .
On critical evaluation, each presentation usually involved one of three scenarios: infection, inadequate soft-tissue coverage, or both. Initial treatment was directed by accurate diagnosis of the primary underlying problem. The choice of treatment modality furthermore depended on the adequacy of local tissues, the severity of infection and exposure, the willingness of the surgeon, and most importantly, the wishes of the patient. Implant salvage was not indicated in patients who were noncompliant or not motivated to pursue salvage.
Initially, if infection was suspected, treatment commenced with wound or fluid culture (if possible) and empiric antibiotic therapy. The initial response to antibiotic therapy was important. In some instances, early antibiotic intervention cured or quieted the infection, thereby "down-staging" the severity and avoiding surgical intervention altogether or permitting an attempt at salvage with surgical intervention in cases where a severe infection became mild, localized, or indolent.
In the setting of persistent mild infection (either de novo or after antibiotic therapy), further reduction of the bacterial level through surgical methods was successful. The affected site required further "débridement," which included partial or total capsulectomy, implant exchange, device location change, pocket curettage, pulse lavage, change of instruments to a clean setup after débridement, and eventual pocket closure, usually with a closed-suction drainage catheter.
In the setting of severe infection alone, antibiotic therapy often down-staged the problem to a mild or localized indolent infection, with or without threatened device exposure (group 1 or 4, Table I ) amenable to the above treatment strategies. If the situation did not improve, device removal was indicated. The nature of the actual infection may influence the ultimate outcome as well. Organisms such as common skin flora (e.g., Staphylococcus aureus) may be treated with a high success rate, but organisms such as Pseudomonas species or Gram-negative rods may not be as easily treated and device removal is more likely indicated. Moreover, if overwhelming localized infection or systemic signs of infection persist, one should likely forgo further salvage attempts.
In cases of threatened or actual exposure, if sufficient local tissue is present, local tissue rearrangement may be adequate. If local tissue is not adequate, a distant flap should be used for coverage. This is obviously more easily done in reconstruction patients as compared with augmentation patients. Furthermore, in the setting of actual device exposure, the assumption is made that contamination or mild infection is present even though there may be no clinical evidence of infection. Thus, initially, the patient is covered with antibiotics, the device is removed, a capsulectomy is performed, the pocket is curetted, the instrument set is changed to a clean set, a new device is placed, and closure is performed with local or distant tissue. If a flap was utilized in the initial operation before implant exposure and this distant tissue is unavailable for a salvage procedure, the implant is removed in favor of a delayed reinsertion.
Those patients with concurrent infection and threatened or actual device exposure present the greatest management challenges. If the infection is mild from the outset or is "down-staged" or controlled with antibiotic therapy, salvage attempts may be attempted by simultaneously solving the soft-tissue deficit. If initial infection is overwhelming or antibiotic therapy is unable to "down-stage" the infection, the authors recommend foregoing further salvage attempts and removal of the implant. Delayed reconstruction is usually possible.
In the current series, patients at the extremes of clinical presentation involved few diagnostic or treatment dilemmas. Group 1 patients with mild infections were treated solely with antibiotic therapy with good results. The group 5 and 7 patients (n ϭ 3), those with severe infections in the setting of threatened or actual exposure, were not offered a salvage procedure and had their implant removed.
Patients with mild infection alone or patients with threatened or actual exposure with mild or no infection (groups 1, 3, 4, and 6) had a high likelihood of successful implant salvage (18 of 19, 95 percent). In reality, several of those patients in our series whose implant was not salvaged were not true failures, as salvage attempts were not offered.
In this current study, six patients ultimately required removal of their prosthesis. After explantation, two patients underwent successful delayed reconstruction with a two-stage implant procedure. As in prior studies, 2 we found that after explantation, delayed reinsertion of a breast prosthesis did not adversely affect the ultimate aesthetic outcome. With this knowledge, immediate salvage attempts, even if unsuccessful, may not adversely affect future reconstruction should initial attempts fail.
CONCLUSIONS
Through review of this series of patients, the authors have developed treatment guidelines for implant salvage in the setting of infection or device exposure. Although device removal and delayed reinsertion remains the most conservative, safe, and predictable strategy, immediate salvage may often be possible. The degree of infection, response of the infection to initial antibiotic therapy, and availability of adequate soft-tissue coverage are important factors when making decisions and planning strategy in the management of these patients. Aggressive salvage measures also require a willingness to attempt salvage on the part of both the patient and the surgeon. Finally, because there are choices available, it is important to clearly communicate to the patient the relative risks and alternatives.
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